Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
Randomized Double-Blind 2-Period Multiple Dose Crossover Study to Evaluate the Efficacy and Safety of AD113 vs Atomoxetine in OSA Patients With Hypertension
Sponsor: Apnimed
A PHASE2 clinical study on Hypertension and Obstructive Sleep Apnea, this trial is completed. The trial is conducted by Apnimed and has accumulated 9 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Apnimed
For direct contact, visit the study record on ClinicalTrials.gov .